1: Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. Related Articles, Links
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Oncogene. 2002 Dec 12;21(57):8804-16.
PMID: 12483533 [PubMed - in process]
2: Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Related Articles, Links
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
Mol Cancer Ther. 2002 Oct;1(12):1115-24.
PMID: 12481435 [PubMed - in process]
3: Kindler T, Breitenbuecher F, Marx A, Hess G, Gschaidmeier H, Gamm H, Kirkpatrick CJ, Huber C, Fischer T. Related Articles, Links
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Blood. 2002 Dec 12 [epub ahead of print]
PMID: 12480706 [PubMed - as supplied by publisher]
4: Skorski T. Related Articles, Links
BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability.
Oncogene. 2002 Dec 9;21(56):8591-604.
PMID: 12476306 [PubMed - in process]
5: Arlinghaus RB. Related Articles, Links
Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
Oncogene. 2002 Dec 9;21(56):8560-7.
PMID: 12476302 [PubMed - in process]
Time used: 46 miliseconds.

Webpage designed by Dr. Xueliang Fang, last updated on 3/10/2005